NCI CCR GU Malignancies

@nciccr_gmb

Finding new treatments for with GU malignancies including . Official Twitter account of the NCI GMB. Privacy:

Vrijeme pridruživanja: veljača 2016.

Tweetovi

Blokirali ste korisnika/cu @nciccr_gmb

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @nciccr_gmb

  1. proslijedio/la je Tweet
    22. sij

    Nice work by Dr. Kieth Schmidt of Figg Lab Rationale supporting with +NLG207(in pts already treated with enzalutamide) trial:

    Poništi
  2. proslijedio/la je Tweet
    24. sij

    Dr.Rosandra Kaplan presents a tour de force on the early/pre-metastatic niche in . Preliminary data also suggests that can be a key player in activation in this setting.

    Poništi
  3. proslijedio/la je Tweet
    10. sij

    Delighted to have the ever thoughtful and brilliant give grand rounds at

    Poništi
  4. 10. sij

    Delighted to have the ever thoughtful and brilliant give grand rounds at

    Poništi
  5. proslijedio/la je Tweet
    1. sij

    To those who look beyond their own dire condition to create a greater awareness and push for culture change that hopefully will prevent many cancers for generations. Thanks Michael for the tangible difference you have made.

    Poništi
  6. proslijedio/la je Tweet
    21. pro 2019.

    Happy holidays 2019 from our NCI team-family, to yours!

    Poništi
  7. proslijedio/la je Tweet
    20. pro 2019.

    The society for of cancer () consensus statement on immunotherapy for the treatment of advanced just out in

    Poništi
  8. proslijedio/la je Tweet
    Poništi
  9. Poništi
  10. proslijedio/la je Tweet
    8. stu 2019.

    . gives a wonderful (and short) overview of his project as a Fellowship co-sponsored by and . This QuEST study design was published in .

    Poništi
  11. proslijedio/la je Tweet
    8. stu 2019.

    . gives a great (short) talk about a study he helped design as an Fellow combining tumor targeted cytokine (NHS-IL12) with bintrafusp Alfa (M7824) +/- SBRT for GU cancers. Study has “may proceed” letter from now at IRB.

    , , i još njih 3
    Poništi
  12. continues to be a theme suppressing the potential for in picking up from the Coffey – Holden meeting this summer. Could be a good target?

    Poništi
  13. proslijedio/la je Tweet
    24. lis 2019.

    Dr. Ajjai Alva discusses loss in and potential for in this subset of patients. A prospective trial is underway.

    Poništi
  14. proslijedio/la je Tweet
    24. lis 2019.

    Beautiful presentation by on cdk12 loss subtype in prostate cancer (7% subset)

    , , i još njih 2
    Poništi
  15. proslijedio/la je Tweet

    This year's Prize for Clinician-Scientists recipient is Dr. James Kochenderfer of at ! Congrats, Dr. Kochenderfer! Read more:

    Poništi
  16. proslijedio/la je Tweet
    14. lis 2019.

    We are very proud to support Dr. Adelaiye-Ogala and Dr. Bishiri who are our latest PCF Young Investigators. This honor will not only provide incredible opportunities for meaningful scientific collaborations but most importantly can lead to impactful advances for our patients.

    Poništi
  17. Poništi
  18. proslijedio/la je Tweet
    20. lis 2019.

    Delighted to see many good friends last night Gala. So honored to be there for presentation of an award to Paul Schellhammer. He has done so much for and is such a humble gentleman. Lovely to also see Lenny Gomella, & .

    Poništi
  19. Poništi
  20. proslijedio/la je Tweet

    “53 years in MLB...I understand teams”. Baseball legend Reggie Jackson (Mr. October) talks about the importance of teamwork in progress for cancer research. Thank you for the inspiration Mr Jackson!!@KimmelCancerCtr

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·